Editas Medicine to Present at the 37th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019, at 9:00 a.m. PT (12:00 p.m. ET) in San Francisco, CA.

A live webcast of the presentation and question and answer session will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com.  An archived replay will be available for approximately 30 days following the presentation.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Contacts

Media:
Cristi Barnett   
(617) 401-0113
cristi.barnett@editasmed.com

Investors:
Mark Mullikin
(617) 401-9083
mark.mullikin@editasmed.com